Domov › Nemalicelični pljučni rak › Michigan › Ann Arbor

Klinične študije za Nemalicelični pljučni rak v Ann Arbor, MI

26 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Ann Arbor in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Vključevanje udeležencevFaza 3

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7 mi stran
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
in še 4

Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Vključevanje udeležencevFaza 2

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
Chelsea Hospital, Chelsea · 15 mi stran
in še 3

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07293247

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Vključevanje udeležencevFaza 3

University of Michigan Rogel Cancer Center, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi stran
in še 2

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Vključevanje udeležencevFaza 3

Trinity Health Ann Arbor Hospital, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06881784

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Vključevanje udeležencevFaza 2

University of Michigan Health System, Ann Arbor
Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti · 7 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Vključevanje udeležencevFaza 2

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7 mi stran
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
in še 4

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT03191149

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Vključevanje udeležencevFaza 1

University of Michigan Health Systems, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07140016

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Vključevanje udeležencevFaza 1/2

University of Michigan Medical School Rogel Cancer Center, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07629960

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Vključevanje udeležencevFaza 3

Clinical Study Site, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06767514

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Vključevanje udeležencevFaza 2

University of Michigan, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 10. sep. 2026 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Vključevanje udeležencevFaza 1

University of Michigan, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Vključevanje udeležencevFaza 3

University of Michigan, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06119581

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Vključevanje udeležencevFaza 3

Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552), Ypsilanti · 7 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06422143

Gilteritinib for the Treatment of ALK NSCLC

Vključevanje udeležencevFaza 1

University of Michigan Comprehensive Cancer Center, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 26. jun. 2026 · NCT06225427

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Vključevanje udeležencevFaza 1

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor

Starost 18 in več · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT04777994

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Vključevanje udeležencevFaza 2

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7 mi stran
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
in še 4

Starost 18 in več · Vsi spoli · Posodobljeno 3. jun. 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Vključevanje udeležencevFaza 2

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi stran
in še 1

Starost 18 in več · Vsi spoli · Posodobljeno 6. maj 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Vključevanje udeležencevFaza 2/3

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi stran
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Vključevanje udeležencevFaza 2

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7 mi stran
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
in še 4

18 Minutes · Vsi spoli · Posodobljeno 5. maj 2026 · NCT06031688